LivaNova PLC 2Q 2026: Revenue $390.59M, EPS $1.93— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.LivaNova PLC reported Q2 2026 revenue of $390.59M, up 10.8% YoY, and diluted EPS of $1.93, a 286% increase from the prior year. Net income rose to $108.57M. Growth was driven by higher volumes and favorable pricing in Cardiopulmonary and Neuromodulation segments. The company is managing supply chain and FX risks while advancing R&D for OSA devices.
LivaNova PLC reported second-quarter 2026 results with revenue of $390.59M, up 10.8% from $352.52M a year earlier, and diluted EPS of $1.93 versus $0.5 in the prior-year quarter as net income rose to $108.57M from $27.16M.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $390.59M | $352.52M | 10.8% |
| Net income² | $108.57M | $27.16M | 299.7% |
| Diluted EPS³ | $1.93 | $0.5 | 286% |
¹ Reported as “Net revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted earnings (loss) per share”.
Business Highlights
- Revenue growth was driven by higher volumes and favorable realized pricing across segments, with net revenue up 10.8% in the quarter and 12.5% year-to-date.
- Cardiopulmonary momentum was led by Essenz Perfusion System sales and strong consumables demand in Europe.
- Neuromodulation grew about 10%, supported by VNS Therapy and progress on OSA device development, including PMA for aura6000 in March 2026.
- Management is addressing supply chain, FX, and tariff impacts through supply agreements and monitoring trade policy risks while increasing R&D investment for OSA neurostimulation and next‑generation device commercialization.
Original SEC Filing: LivaNova PLC [ LIVN ] - 10-Q - Aug. 05, 2026